Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Axon Enterprise Inc (AXON) vs Viatris Inc (VTRS) Price & Performance

Axon Enterprise IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Axon Enterprise Inc vs Viatris Inc — how do they compare? Axon Enterprise Inc trades at $596 (market cap $51.69B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Axon Enterprise Inc is far larger — about 2.8× Viatris Inc's market cap, and Viatris Inc pays a 2.95% dividend while Axon Enterprise Inc pays none. Which is the better fit depends on your goals.

AXONVTRS
Market Cap
$51.69B$18.69B
Sector
TechnologyHealth
52-Week High
$791.62$17.86
52-Week Low
$345.94$9.49
Enterprise Value
$52.83B$30.80B
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Axon Enterprise Inc

Axon Enterprise trades at $595.63, showing slight consolidation after recent strength with a bullish technical outlook. The company delivered strong Q2 2026 results with 35% revenue growth and raised full-year guidance, though valuation metrics remain elevated with a P/E of 265. Analyst sentiment is overwhelmingly positive with 81% buy ratings and a $685 consensus target.

Axon's razor-and-blade model drives hardware adoption and high-margin software growth, supported by AI capabilities and $15.1B in future contracted bookings. Key risks include valuation concerns, gross margin pressure from service mix, and execution challenges in scaling new products. The stock offers growth exposure but requires monitoring of margin trends.

Viatris Inc

Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.

Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Axon Enterprise Inc

Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.

Read more on AXON

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS